A 72-year-old woman developed EMPACT (Erythema multiforme associated with phenytoin and cranial radiation therapy) syndrome during treatment with phenytoin for prophylactic anticonvulsant therapy
By continuing to use our website, you are agreeing to our use of cookies
Warnings Background Intracranial malignancies (primary and metastatic) are often complicated by seizure activity
[1][2][3] @article{osti_5430778, title = {Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin}, author = {Delattre, J Y and Safai, B and Posner, J B}, abstractNote = {In 15 months we encountered eight patients with intracranial tumors who developed erythema multiforme (EM) or erythema multiforme bullosa (Stevens-Johnson syndrome)
Phenytoin is an antiepileptic drug which can be used in the treatment of epilepsy
We herein present the case of Phenytoin induced Erythema Multiforme
In 15 months we encountered eight patients with intracranial tumors who developed erythema multiforme (EM) or erythema multiforme bullosa (Stevens-Johnson syndrome)
[1] Higher risk of severe adverse drug reactions was reported Nursing questions and answers
Herein, we report a 36-year-old female with breast carcinoma, who developed EMPACT syndrome after treating with cranial radiation therapy for brain metastasis and phenytoin for seizure prophylaxis
A 37-year-old female developed erythema multiforme 17 days after beginning carbamazepine for complex partial seizures
Increased clinical suspicion and prompt histopathological examination are crucial for early diagnosis
It is also a Vaughan-Williams class IB antiarrhythmic agent, although it is now infrequently used for that indication
Erythema multiforme is caused by a cell-mediated immune response, and infections are associated with 90% of cases
Erythema multiforme: case report
11
[1] Higher risk of severe adverse drug reactions was reported In 15 months we encountered eight patients with intracranial tumors who developed erythema multiforme (EM) or erythema multiforme bullosa (Stevens-Johnson syndrome)
1016/j
An event is serious (FDA MedWatch definition) when the patient outcome is: A 60-year-old woman developed erythema multiforme after receiving phenytoin with concurrent radiotherapy
The etiology of pediatric EM involves infections, medications, autoimmune diseases, and genetic factors
The infusion completed in ED and he is now on the children's ward
Subsequently, she developed facial swelling on right side and blanchable erythematous maculopapular rash with atypical target lesions all over the body after 11/2 months [sic] of phenytoin Erythema multiforme (EM) associated with phenytoin and cranial radiation therapy (EMPACT) is the term that describes this reaction
This clinical entity is named after as an acronym of components which are Erythema Multiforme associated with Phenytoin And Cranial RadiationTherapy as EMPACT @article{Joseph2021AnAI, title={An adverse impact of concurrent cranial irradiation therapy and phenytoin-erythema multiforme, phenytoin, and cranial irradiation therapy syndrome}, author={Sharon Kunnath Joseph and Myfanwy D'souza and Aryambika Krishnan and Jacintha Martis}, journal={Turkish Journal of Dermatology}, year={2021}, url={https Springer Medicine delivers trusted medical education to specialist doctors in easily digestible formats
Erythema multiforme is characterised by target-like lesions Erythema is a skin condition characterized by redness or rash
Case report; Published: 14 January 2013; A 53-year-old woman developed erythema multiforme following prophylactic anticonvulsant treatment with phenytoin, and cranial radiation
In these patients, generalized severe adverse drug reactions such as erythema multiforme (EEM) may occur
Then she was treated with tablet hydroxyzine 10 mg, tablet prednisolone 20 mg, liquid paraffin external applications (E/A), momate lotion E/A
It is an eruption of classic target lesions on the extremities associated with mild fever and malaise
combined Erythema Multiforme, Phenytoin And Cranial RadiationTherapy components and named a new syndrome as EMPACT syndrome in the literature
Phenytoin (Dilantin) is typically employed as prophylactic anticonvulsant in this setting
Herein, we report a 36-year
Phenytoin has been associated with variety of adverse skin reactions including urticaria, erythroderma, erythema multiforme (EM), Stevens-Johnson syndrome, and toxic
Gingival hyperplasia
A case of erythema multiforme associated with prophylactic use of phenytoin during cranial radiation therapy is reported
During this treatment, erythematous lesions and blisters were observed first on her face and trunk and then spreading to the entire body
Interactions
Erythema and tenderness were prominent at the end of the infusion and again at 24 hours
A new rash developed and phenytoin therapy was stopped
Background Intracranial malignancies (primary and metastatic) are often complicated by seizure activity
g
[22] Lupus-like symptoms have been described for phenytoin
The prophylactic use of phenytoin during and after brain surgery and cranial irradiation is a common measure in brain tumor therapy
36 Accesses
1
A 65-year-old elderly female presented to our hospital with a 3 days history of itching all over the body, multiple reddish lesions over bilateral arms, forearms, anterior aspect of chest, trunk, bilateral palms and soles
Twenty-nine complications were burning pain at the IV site, and 36 were related to excessive total
A 60-year-o ‘Erythema Multiforme associated with Phenytoin And Cranial radiation Therapy’ (EMPACT) is a very rare clinic situation and classified in EM-like drug reactions
06
Case report; Published: 14 January 2013; Volume 1351, page 35, (2011) Cite this article; Download PDF -year-old man with metastatic lung cancer developed erythema multiforme during prophylactic anticonvulsant therapy with phenytoin, and cranial radiation
Ben, aged 12 years, had a peripheral VAD inserted for administration of IV phenytoin during a seizure
This activity describes the indications, action, and contraindications for phenytoin as a valuable agent in the treatment of epilepsy